Loading organizations...
§ Public · Berkeley, CA, USA
Biotechnology company develops CRISPR-based genome editing for oncology therapeutics, including CAR-T cell therapies.
Caribou Biosciences is a clinical-stage biotechnology company based in Berkeley, California, that develops CRISPR-based genome editing technologies for therapeutic applications, specifically targeting oncology and various blood cancers. The organization has raised over $800 million in total funding to date, a financial figure which includes approximately $304 million generated from its initial public offering in 2021. The firm advances its proprietary platform through clinical trials, recently presenting positive Phase 1 data for its CB-010 therapy in lymphoma patients while progressing additional treatments for multiple myeloma and solid tumors. To support its drug discovery and development pipeline, the enterprise has established strategic partnerships and secured financial investments from major industry players such as Novartis, Pfizer, and Third Rock Ventures. Caribou Biosciences was originally founded in 2011 by Jennifer Doudna, Rachel Haurwitz, James Berger, and Martin Jinek.
Caribou Biosciences has raised $161.0M across 3 funding rounds.
Caribou Biosciences has raised $161.0M in total across 3 funding rounds.
# Caribou Biosciences: A Clinical-Stage Biotech Pioneer
Caribou Biosciences is a clinical-stage biopharmaceutical company, not a technology company in the traditional sense—though it is deeply rooted in technology innovation. The company develops genome-edited allogeneic cell therapies for cancer and genetic diseases, leveraging proprietary CRISPR-based gene-editing technology as its core scientific foundation.[1][2]
Caribou focuses on transforming cancer treatment and genetic disease management through off-the-shelf cell therapies. The company develops engineered T-cell and NK-cell therapies designed to improve safety, efficacy, and persistence in patients with hematologic and solid tumor malignancies.[2] Beyond oncology, Caribou is advancing in vivo editing programs targeting monogenic disorders, including Duchenne muscular dystrophy and familial amyloidosis.[2]
The company's mission centers on addressing a critical limitation of existing cell therapies: the complexity and cost of manufacturing patient-specific treatments. By creating allogeneic (donor-derived) therapies that work across patient populations, Caribou aims to democratize access to advanced cell therapies while reducing manufacturing variability.[1]
Caribou was established in 2011 and co-founded by Nobel laureate Jennifer Doudna, one of the pioneers of CRISPR gene-editing technology.[2] The company emerged from groundbreaking research at UC Berkeley, where Doudna and Dr. Luciano Marraffini developed foundational CRISPR-Cas9 innovations.[1] Caribou holds licenses to foundational CRISPR intellectual property from the University of California, positioning it at the forefront of genome engineering.[2]
The company completed its initial public offering in July 2021, raising $202 million and marking its transition from private research to public clinical-stage development.[2] Since then, Caribou has focused on progressing its clinical pipeline and expanding manufacturing capabilities to support its growing roster of investigational therapies.[2]
Caribou operates at the intersection of two transformative biotech trends: CRISPR gene editing and allogeneic cell therapy. The timing is critical—cell therapy has moved from experimental to clinical reality, yet manufacturing remains a bottleneck. Caribou's approach addresses this by engineering universal donor cells rather than patient-specific treatments, potentially unlocking broader patient access and faster treatment timelines.
The company's work influences the broader ecosystem by demonstrating that CRISPR technology can move beyond theoretical applications into clinical practice. As regulatory pathways for gene-edited therapies mature, Caribou's clinical progress serves as a proof-of-concept for the entire field.[2]
Caribou stands at an inflection point. With its next earnings announcement scheduled for March 9, 2026, the company is advancing multiple clinical programs while navigating the capital-intensive nature of cell therapy development.[1] Wall Street analysts are cautiously optimistic, with 7 out of 9 analysts rating the stock as "Buy" and a median price target of $7.50.[5]
The company's future hinges on clinical trial success and manufacturing scale-up. If Caribou can demonstrate that its genome-edited allogeneic therapies match or exceed the efficacy of autologous approaches while reducing costs, it could reshape cancer treatment economics. The broader trend toward off-the-shelf cellular medicines—driven by manufacturing innovation and regulatory clarity—positions Caribou as a potential category leader in a market that could transform oncology over the next decade.
Caribou Biosciences has raised $161.0M across 3 funding rounds. Most recently, it raised $120.0M Series C in March 2021.
Caribou Biosciences has raised $161.0M in total across 3 funding rounds.
Caribou Biosciences's investors include Farallon Capital Management, Santhosh Palani, PhD, CFA, Jeffrey Long-McGie, 1435 Capital Management, 6th Man Ventures, Afore Capital, DFJ, E1 Ventures, Flucas Ventures, Founders Co-op, Heavybit, Invariantes Fund.